diabetes close up
Subscribe to Diabetes Close Up (DCU). With a year's subscription, you'll receive:
- In-depth coverage of diabetes industry news and research trends
- Alerts on breaking news or important research
- Real time updates on conference proceedings
- Full access to our extensive archives
A LOOK INSIDE THE LATEST ISSUE OF DCU
The ACCORD trial was a major topic in last month's DCU, but we are not done talking about it! Last month, I expressed concern that ACCORD would be misinterpreted and generalized by the diabetes community. While on the whole the diabetes community appears to be embracing the conclusion that the ACCORD trial applies only to a specific group of patients with advanced type 2 diabetes, and that the current ADA guideline (which suggests targeting an A1c of 7.0%) is appropriate, we did hear some things at AADE that gave us pause (we'll be out with our full AADE summary next month). ACCORD may not have gone the way that many people expected, but the results of the study do not conflict with previous research. Rather, as Dr. Kendall indicated, they refine our understanding of intensive glucose control.
Looking forward, EASD (Rome, Italy) feels like it is around the corner (we can't wait for all the cappuccino), and the oral sessions and poster sessions are chock-full of interesting information. On the drug side, we are particularly looking forward to seeing results from Biodel on VIAject, from BMS/AZ on Onglyza, and from Diamyd on its rhGAD65 vaccination. There are several oral sessions and posters on exenatide and liraglutide as well, and we will be taking careful note of the results and conclusions they come to about these two drugs. On the device side, it appears there is a great deal of attention being given to continuous glucose monitoring (CGM). Following on an incredible artificial pancreas workshop sponsored by FDA, NIH, and JDRF last month, we hope to see more about CGM, integrating CGM with insulin pumps, and moving closer to an artificial pancreas.
If you'd like to read more, then Subscribe to Diabetes Close Up.
IN-DEPTH INTERVIEWS WITH DIABETES AND OBESITY INSIDERS
DCU co-hosts with biotech expert Mike King a real-time discussion on ACCORD with noted endocrinologists Dr. Jay Skyler and Dr. Irl Hirsch. Read More
DCU talks to noted cardiologist Dr. Steven Nissen about Avandia. Read More
DCU talks to John Eng, who discovered Exenatide (exendin-4). Read More
DCU talks to Children With Diabetes founder Jeff Hitchcock about what industry does well and what it needs to do better. Read More
DCU talks to obesity expert Dr. Xavier Pi-Sunyer about clincial trials, prospects for new therapies, and his view of the "state of the state." Read More
DCU talks to Dr. Irl B. Hirsch about his thoughts on continuous glucose monitoring and glycemic variability, incretins, inhaled insulin, and how diabetes care in America is in a relative state of crisis. Read More
DCU talks to Dr. Zach Bloomgarden about the latest controversy with Galvus, the importance of rimonabant, the potential of continuous glucose monitoring, and much more. Read More
welcome!
New to Close Concerns?
Subscribe
Already registered?
Log in
WHAT WE DO
consulting
strategic advice and comprehensive information for those interested in the diabetes industry
diabetes close up
our monthly newsletter
industry reports
periodically we take the long view on trends or on specific breakthroughs.
TEAM
web log
Click here to view the entire Close Concerns weblog
Diabetes Roundup II
Read our eight page introduction to Diabetes Round Up II here
Close Concerns is pleased to announce Diabetes Roundup II, a unique 400+ page compilation of observations on the diabetes and obesity industries - a followup to our Diabetes Roundup I, published in 2004. Diabetes Round Up II features:
- In-depth reviews of the top eight academic diabetes conferences over the last 18 months (ADA, ADA Postgraduate Sessions, AADE, AACE, EASD, DTT, NAASO, the 1st Annual Amsterdam Diabetes Forum)
- Detailed insights on the dozen additional conferences of note (Canadian Diabetes Association; 1st International Conference on Pre-Diabetes and the Metabolic Syndrome; AIDPIT: Artificial Insulin Delivery Systems, Pancreas, and Islet Transplantation; ACE/AACE Consensus Conference on Inpatient Diabetes and Glycemic Control; and the Levine Symposium, among others)
- Detailed financial models for the $6 billion blood glucose monitoring and $1 billion insulin pump markets
- An-depth drug pipeline database of 50-plus companies developing nearly 200 diabetes and obesity therapies
- Our selection of the top 50 diabetes-related articles in medical journals over the last year (JAMA, NEJM, Diabetes Care, The Diabetes Educator) and detailed reviews of each
- Our reports on the major analyst meetings over the last 12-18 months (Animas, BMS, Lilly, Medtronic, Merck, Roche, Pfizer, Sanofi, Mannkind)
- A detailed calendar of 30 important upcoming diabetes meetings in 2006 and 2007
- The best of DCU: our top five stories from DCU #1 - #55
- The Close Concerns High Five Awards: our detailed assessment of the top five diabetes products introduced over the last 12-18 months, including Amylin's Symlin and Byetta, Insulet's Omnipod, and Dex Com's STS